New p32/gC1qR Ligands for Targeted Tumor Drug Delivery
0301 basic medicine
Aminopyridines
Bioengineering
Antineoplastic Agents
Breast Neoplasms
Ligands
high-throughput screening
Peptides, Cyclic
Cell Line
Mitochondrial Proteins
Medicinal and Biomolecular Chemistry
Mice
03 medical and health sciences
Drug Delivery Systems
Cell Line, Tumor
Medicinal and biomolecular chemistry
Nanotechnology
cancer
Animals
Humans
Cancer
Cyclic
Tumor
Organic Chemistry
Ethylenediamines
3. Good health
5.1 Pharmaceuticals
Biochemistry and cell biology
Chemical Sciences
drug delivery
peptides
Nanoparticles
nanoparticles
Female
Biochemistry and Cell Biology
Development of treatments and therapeutic interventions
Peptides
Carrier Proteins
Biotechnology
DOI:
10.1002/cbic.201500564
Publication Date:
2016-02-20T16:08:38Z
AUTHORS (12)
ABSTRACT
AbstractCell surface p32, the target of LyP‐1 homing peptide, is upregulated in tumors and atherosclerotic plaques and has been widely used as a receptor for systemic delivery of payloads. Here, we identified an improved LyP‐1‐mimicking peptide (TT1, CKRGARSTC). We used this peptide in a fluorescence polarization‐based high‐throughput screening of a 50 000‐compound chemical library and identified a panel of compounds that bind p32 with low micromolar affinity. Among the hits identified in the screen, two compounds were shown to specifically bind to p32 in multiple assays. One of these compounds was chosen for an in vivo study. Nanoparticles surface‐functionalized with this compound specifically adhered to surfaces coated with recombinant p32 and, when injected intravenously, homed to p32‐expressing breast tumors in mice. This compound provides a lead for the development of p32‐targeted affinity ligands that circumvent some of the limitations of peptide‐based probes in guided drug delivery.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (33)
CITATIONS (79)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....